Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Digi_Sight_Technologies
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:business_model |
Research and development focused
|
| gptkbp:ceo |
gptkb:Dr._Sean_Ianchulev
|
| gptkbp:clinical_trial |
gptkb:battle
Ongoing clinical trials Phase 3 clinical trials Published clinical data |
| gptkbp:collaborations |
Academic institutions
Collaborations with research institutions |
| gptkbp:community_involvement |
Community outreach programs
|
| gptkbp:competitors |
Other biotech companies
|
| gptkbp:conference |
Annual shareholder meetings
|
| gptkbp:developer |
Investing in technology development
|
| gptkbp:employees |
50-100
|
| gptkbp:financial_performance |
Quarterly earnings reports
Reported financial results |
| gptkbp:focus |
gptkb:sneaker
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:founder |
gptkb:Eric_A._Acher
|
| gptkbp:future_plans |
Expand into new markets
|
| gptkbp:governed_by |
Active business development efforts
|
| gptkbp:grants |
Received research grants
|
| gptkbp:headquarters |
gptkb:Borough
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eyenovia, Inc.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:invention |
Multiple patents granted
|
| gptkbp:investment |
Institutional investors
Venture capital funding Active investor relations program Volatile stock performance |
| gptkbp:language_of_instruction |
Diverse product pipeline
|
| gptkbp:leadership |
Experienced management team
|
| gptkbp:local_newspaper |
Regular press releases
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
Conducting market research
Upcoming product launches |
| gptkbp:market_cap |
Approximately $100 million
|
| gptkbp:marketing_strategy |
Targeted marketing strategy
|
| gptkbp:mission |
Transforming the treatment of eye diseases.
|
| gptkbp:partnerships |
Various pharmaceutical companies
Partnerships with healthcare providers Exploring partnership opportunities |
| gptkbp:products |
gptkb:Microdose_Therapeutics
Innovative product development AP X3330 Mydcombi Vesneo |
| gptkbp:regulatory_compliance |
FDA approved products
Ongoing regulatory submissions |
| gptkbp:research_focus |
Novel drug delivery systems
Glaucoma and other eye conditions |
| gptkbp:scholarships |
Seeking financial support
|
| gptkbp:social_responsibility |
gptkb:Community_engagement_initiatives
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
gptkb:battle |
| gptkbp:strategic_importance |
Expand product pipeline
|
| gptkbp:sustainability |
gptkb:Sustainability_initiatives
|
| gptkbp:symbol |
EYEN
|
| gptkbp:technology |
Microdosing technology
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
Focus on improving clinical outcomes
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:type_of_care |
Patient engagement initiatives
|
| gptkbp:vision |
Innovative therapies for patients.
|
| gptkbp:website |
www.eyenovia.com
|